Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Comparison of spirometric markers of severity and reversibility in patients with asthma and/or COPD in NOVELTY

Rod Hughes, Ricardo Del Olmo, Barry Make, David Price, Alvar Agustí, Eleni Rapsomaniki, Hana Müllerová, Jørgen Vestbo
European Respiratory Journal 2020 56: 3759; DOI: 10.1183/13993003.congress-2020.3759
Rod Hughes
1AstraZeneca, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rod.hughes@astrazeneca.com
Ricardo Del Olmo
2Diagnostic and Treatment Department, Hospital de Rehabilitación Respiratoria "María Ferrer" and IDIM CR, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barry Make
3National Jewish Health and University of Colorado Denver, Denver, CO, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Price
4Observational and Pragmatic Research Institute, Singapore, and Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alvar Agustí
5Respiratory Institute, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERES, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eleni Rapsomaniki
1AstraZeneca, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hana Müllerová
1AstraZeneca, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jørgen Vestbo
6University of Manchester and Manchester University NHS Foundation Trust, Manchester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

Background: NOVELTY (NCT02760329) is a global, prospective, observational study of patients with a physician-assigned diagnosis of asthma and/or COPD. Pre- and post-bronchodilator (BD) spirometry was performed at baseline.

Objective: To compare spirometric markers of airflow obstruction and reversibility across the spectrum of obstructive lung disease.

Methods: Pre- and post-BD FEV1, FVC, FEV1/FVC, FEF25-75%, PEFR and BD reversibility (FEV1 increase ≥200 mL and ≥12%) were compared across physician-assigned diagnosis and severity groups.

Results: In the 9,180 patients assessed, mean pre-BD FEV1, FEF25-75% and PEFR, and post-BD FEV1/FVC decreased with increasing severity (Table). Across all severities, spirometric markers were lower in patients with COPD vs asthma; asthma+COPD lay in between. Reversibility was similar across all diagnoses and severities, with a greater FEV1 reversibility with more severe disease. BD reversibility was comparable across all groups, but was lower for those with severe COPD vs severe asthma and asthma+COPD for FEF25-75% and PEFR.

Conclusions: Increasing physician-assigned severity was associated with greater airflow limitation across all spirometric measures, particularly in patients with COPD. However, reversibility did not differentiate asthma from COPD. The use of reversibility criteria to distinguish diagnoses for entry into clinical trials must be questioned.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

  • COPD - diagnosis
  • Monitoring
  • Asthma - diagnosis

Footnotes

Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3759.

This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2020
Previous
Back to top
Vol 56 Issue suppl 64 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of spirometric markers of severity and reversibility in patients with asthma and/or COPD in NOVELTY
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Comparison of spirometric markers of severity and reversibility in patients with asthma and/or COPD in NOVELTY
Rod Hughes, Ricardo Del Olmo, Barry Make, David Price, Alvar Agustí, Eleni Rapsomaniki, Hana Müllerová, Jørgen Vestbo
European Respiratory Journal Sep 2020, 56 (suppl 64) 3759; DOI: 10.1183/13993003.congress-2020.3759

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Comparison of spirometric markers of severity and reversibility in patients with asthma and/or COPD in NOVELTY
Rod Hughes, Ricardo Del Olmo, Barry Make, David Price, Alvar Agustí, Eleni Rapsomaniki, Hana Müllerová, Jørgen Vestbo
European Respiratory Journal Sep 2020, 56 (suppl 64) 3759; DOI: 10.1183/13993003.congress-2020.3759
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • CT evaluations of erector spinae muscle, emphysema, and airway disease for predicting mortality in COPD
  • Alpha-1 antitrypsin deficiency in patients with COPD/emphysema, bronchiectasis and asthma
  • Detecting shortness of breath remotely and accurately using smartphones and vocal biomarkers
Show more Monitoring airway disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society